• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 8:48:51 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care
    Get the next $CRY alert in real time by email
    SC 13G/A 1 d114935dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    CryoLife Inc

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    228903100

    (CUSIP Number)

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 228903100

     

      1.    

      Names of Reporting Persons

     

      Macquarie Group Limited

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Sydney, New South Wales Australia

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      0

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,039,839 deemed beneficially owned due to reporting person’s ownership of Macquarie Bank Limited, Macquarie Investment Management Holdings Inc., Macquarie Investment Management Business Trust, and Macquarie Investment Management Global Limited whose individual holdings are shown on the following forms.

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      5.25%

    12.  

      Type of Reporting Person (See Instructions)

     

      HC

     

    Page 2 of 14


    CUSIP No. 228903100

     

      1.    

      Names of Reporting Persons

     

      Macquarie Bank Limited

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Sydney, New South Wales, Australia

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      0

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,039,839 deemed beneficially owned due to reporting person’s ownership of Macquarie Investment Management Holdings Inc., Macquarie Investment Management Business Trust, and Macquarie Investment Management Global Limited whose individual holdings are shown on the following forms.

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      5.25%

    12.  

      Type of Reporting Person (See Instructions)

     

      CO

     

    Page 3 of 14


    CUSIP No. 228903100

     

      1.    

      Names of Reporting Persons

     

      Macquarie Investment Management Holdings Inc

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      State of Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      2,028,228

       6.   

      Shared Voting Power

     

      0

       7.   

      Sole Dispositive Power

     

      2,028,228

       8.   

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,039,061 deemed beneficially owned due to reporting person’s ownership of Macquarie Investment Management Business Trust

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☒

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      5.25%

    12.  

      Type of Reporting Person (See Instructions)

     

      HC

     

    Page 4 of 14


    CUSIP No. 228903100

     

      1.    

      Names of Reporting Persons

     

      Macquarie Investment Management Business Trust

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      State of Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      2,028,228

       6.   

      Shared Voting Power

     

      0

       7.   

      Sole Dispositive Power

     

      2,028,228

       8.   

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,039,061

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☒

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      5.25%

    12.  

      Type of Reporting Person (See Instructions)

     

      IA

     

    Page 5 of 14


    CUSIP No. 228903100

     

      1.    

      Names of Reporting Persons

     

      Macquarie Investment Management Group Limited

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Sydney, New South Wales, Australia

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      778

       6.   

      Shared Voting Power

     

      0

       7.   

      Sole Dispositive Power

     

      778

       8.   

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

    778

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      0.00%

    12.  

      Type of Reporting Person (See Instructions)

     

      CO

     

    Page 6 of 14


    Item 1.

     

      (a)

    Name of Issuer

     

       

    CryoLife Inc.

     

      (b)

    Address of Issuer’s Principal Executive Offices

     

       

    1655 Roberts Blvd NW, Kennesaw, GA 30144

    Item 2.

     

      (a)

    Name of Person Filing

     

       

    This Schedule 13G is jointly filed by Macquarie Group Limited, Macquarie Bank Limited, Macquarie Investment Management Holdings Inc, Macquarie Investment Management Business Trust, and Macquarie Investment Management Global Limited

      (b)

    Address of Principal Business Office or, if none, Residence

     

       

    The principal business address of Macquarie Group Limited, Macquarie Bank Limited, and Macquarie Investment Management Global Limited is 50 Martin Place Sydney, New South Wales, Australia. The principal business address of Macquarie Investment Management Holdings Inc. and Macquarie Investment Management Business Trust is 2005 Market Street, Philadelphia, PA 19103.

      (c)

    Citizenship

     

       

    Macquarie Group Limited, Macquarie Bank Limited, and Macquarie Investment Management Global Limited—Sydney, New South Wales, Australia Corporation Macquarie Investment Management Holdings Inc. and Macquarie Investment Management Business Trust – incorporated or formed under the laws of the State of Delaware.

     

      (d)

    Title of Class of Securities

     

       

    Common Stock

     

      (e)

    CUSIP Number

     

       

    228903100

     

    Item 3.

      

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      

    (a)

      

    ☐

       Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
      

    (b)  

      

    ☐

       Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
      

    (c)

      

    ☐

       Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
      

    (d)

      

    ☐

       Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      

    (e)

      

    ☒

       An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      

    (f)

      

    ☐

       An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
      

    (g)

      

    ☒

       A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
      

    (h)

      

    ☐

       A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      

    (i)

      

    ☐

       A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
      

    (j)

      

    ☐

       A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
      

    (k)

      

    ☐

       Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:____________________________

     

    Page 7 of 14


    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)

    Amount beneficially owned:

    See responses on the cover page hereto.

     

      (b)

    Percent of class:

    See responses on the cover page hereto.

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote

    See responses on the cover page hereto.

     

      (ii)

    Shared power to vote or to direct the vote

    0

     

      (iii)

    Sole power to dispose or to direct the disposition of

    See responses on the cover page hereto.

     

      (iv)

    Shared power to dispose or to direct the disposition of

    0

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

    See Exhibit A.

     

    Item 8.

    Identification and Classification of Members of the Group

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group

    Not applicable.

     

    Page 8 of 14


    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Macquarie Group Limited     

    February 12, 2021

         Date

    /s/ Paul Peduto

        

    /s/ Charles Glorioso

    Signature      Signature

     

    Paul Peduto

    Associate Director

        

     

    Charles Glorioso

    Division Director

     

    Macquarie Bank Limited     

    February 12, 2021

         Date

    /s/ Paul Peduto

        

    /s/ Charles Glorioso

    Signature      Signature

     

    Paul Peduto

    Associate Director

        

    Charles Glorioso

    Division Director

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Macquarie Investment Management Holdings, Inc     

    February 12, 2021

         Date

    /s/ Brian L. Murray

        
    Signature     

     

    Brian L. Murray

    Chief Compliance Officer

        

     

    Macquarie Investment Management Business Trust     

    February 12, 2021

         Date

    /s/ Brian L. Murray

        
    Signature     

     

    Brian L. Murray

    Chief Compliance Officer

        

     

    Page 9 of 14


    EXHIBIT A

    AGREEMENT TO FILE JOINT ACQUISITION STATEMENTS

    AGREEMENT made this 2nd day of FEBRUARY, 2021 by and between Delaware FundsSM by Macquarie listed on Annex A hereto, Macquarie Investment Management Business Trust, Macquarie Investment Management Holdings, Inc, and the Macquarie Parties listed on Annex B hereto (collectively referred to as the “parties”).

    WHEREAS, the parties hereto may be deemed to be the direct or indirect beneficial owners of the same equity securities for the purpose of the reporting requirements of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and

    WHEREAS, the regulations promulgated under Section 13(d) of the Exchange Act permit the joining of such beneficial owners in the filing of a single Joint Acquisition Statement reporting such ownership to the Securities and Exchange Commission.

    NOW, THEREFORE, in consideration of the mutual covenants herein contained, and each of the parties hereto intending to be legally bound, it is agreed as follows:

    1. In the event that any two or more parties shall be deemed to be the direct or indirect beneficial owners of the same equity security required to be reported to the Securities and Exchange Commission such parties may join together in the filing of a Joint Acquisition Statement with respect to that security. Additional persons who may after the date hereof be deemed to be the direct or indirect beneficial owners of the same equity security as a party hereto and required to be reported to the Securities and Exchange Commission (a “New Party”) may be added as a party this agreement by signing a counterpart hereof. An amendment to this agreement is deemed effective upon the signature of such new party and the amendment of the applicable Annex which may be affixed to this agreement as amended. Each party hereto agrees that this agreement, as it may be amended from time to time as provided herein, is a valid and binding agreement of each such party.

    2. With respect to each Joint Acquisition Statement in which a party joins, each party acknowledges that (a) it will be eligible under applicable regulations of the Securities and Exchange Commission to join in the filing and (b) it will be responsible for the timely filing of such statement and any amendments thereto and the completeness and accuracy of the information concerning such party; but each such party shall not be responsible for the completeness and accuracy of the information concerning the other parties making the filing, unless such party knows or has reason to believe that such information with respect to such other parties is inaccurate.

    3. The parties consent to the inclusion of a copy of this agreement as an exhibit to any Joint Acquisition Statement filed on behalf of any of them.

     

    Page 10 of 14


    IN WITNESS WHEREOF, the parties hereto have executed this agreement by their duly authorized officers as of the date set forth above.

    DELAWARE FUNDSSM BY MACQUARIE (listed on Annex A hereto)

    ATTEST BY:

     

    /s/ Brian L. Murray

        

    /s/ David Connor

    Signature      Signature

     

    Brian L. Murray

    Chief Compliance Officer

        

     

    David Connor

    General Counsel

    MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST

     

    /s/ Brian L. Murray

        

    /s/ David Connor

    Signature      Signature

     

    Brian L. Murray

    Chief Compliance Officer

        

     

    David Connor

    General Counsel

    MACQUARIE INVESTMENT MANAGEMENT HOLDINGS, INC.

     

    /s/ Brian L. Murray

        

    /s/ David Connor

    Signature      Signature

     

    Brian L. Murray

    Chief Compliance Officer

        

     

    David Connor

    General Counsel

    THE MACQUARIE PARTIES (LISTED ON ANNEX B HERETO)

    ATTEST BY:

     

    /s/ Paul Peduto

        

    /s/ Charles Glorioso

    Signature      Signature

     

    Paul Peduto

    Associate Director

        

     

    Charles Glorioso

    Division Director

     

    Page 11 of 14


    Annex A— Delaware FundsSM by Macquarie

    DELAWARE GROUP EQUITY FUNDS I

    DELAWARE GROUP EQUITY FUNDS II

    DELAWARE GROUP EQUITY FUNDS IV

    DELAWARE GROUP EQUITY FUNDS V

    DELAWARE GROUP INCOME FUNDS

    DELAWARE GROUP LIMITED-TERM GOVERNMENT FUNDS

    DELAWARE GROUP CASH RESERVE

    DELAWARE GROUP GOVERNMENT FUND

    DELAWARE GROUP STATE TAX-FREE INCOME TRUST

    DELAWARE GROUP TAX-FREE FUND

    DELAWARE GROUP GLOBAL & INTERNATIONAL FUNDS

    DELAWARE GROUP ADVISER FUNDS

    DELAWARE VIP TRUST

    DELAWARE POOLED TRUST

    DELAWARE GROUP FOUNDATION FUNDS

    DELAWARE INVESTMENTS DIVIDEND AND INCOME FUND, INC.

    DELAWARE ENHANCED GLOBAL DIVIDEND AND INCOME FUND

    VOYAGEUR INSURED FUNDS

    VOYAGEUR INTERMEDIATE TAX FREE FUNDS

    VOYAGEUR MUTUAL FUNDS

    VOYAGEUR MUTUAL FUNDS II

    VOYAGEUR MUTUAL FUNDS III

    VOYAGEUR TAX FREE FUNDS

    DELAWARE INVESTMENTS COLORADO MUNICIPAL INCOME FUND, INC.

    DELAWARE INVESTMENTS NATIONAL MUNICIPAL INCOME FUND

    DELAWARE INVESTMENTS MINNESOTA MUNICIPAL INCOME FUND II, INC.

     

    Page 12 of 14


    Annex B — the Macquarie Parties

    Macquarie Group Limited

    Macquarie Bank Limited

    Macquarie Affiliated Managers (USA) Inc.

    Macquarie Affiliated Managers Holdings (USA) Inc.

    Macquarie Americas Holdings Pty Ltd.

    Macquarie B.H. Pty Limited

    Macquarie FG Holdings Inc.

    Macquarie Funding Holdings Inc.

    Macquarie Investment Management Limited

    Macquarie Investment Management Global Limited

    Macquarie Investment Management Australia Limited

    Macquarie Investment Management Austria Kapitalanlage AG

    ValueInvest LUX

     

    Page 13 of 14


    EXHIBIT B

    Powers of Attorney for Macquarie Group Limited and Macquarie Bank Limited incorporated by reference to 13G filings made by Macquarie Group Limited and Macquarie Bank Limited on September 9, 2011.

     

    Page 14 of 14

    Get the next $CRY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRY

    DatePrice TargetRatingAnalyst
    1/7/2022$29.00 → $25.00Equal-Weight
    Morgan Stanley
    7/30/2021$31.00 → $32.00Equal-Weight
    Morgan Stanley
    7/30/2021$38.00 → $39.00Buy
    Needham
    7/15/2021$31.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $CRY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CryoLife Announces Corporate Rebranding and Changes Name to Artivion

    ATLANTA, Jan. 18, 2022 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it was renaming and rebranding itself to Artivion, Inc., effective immediately. Derived from the words "aorta", "innovation", and "vision", the company's new name and brand reflect its evolution to focus on providing innovative technologies to surgeons who treat patients with aortic disease. In conjunction with these changes, effective January 24, 2022, the company will also change its ticker symbol on the New York Stock Exchange to "AORT" from "CRY."

    1/18/22 8:10:00 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum

    ATLANTA, Nov. 9, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that members of management will host one-on-one meetings at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on Thursday, November 18, 2021. Due to the format of this event no webcast will be available. For more information on the company, please visit CryoLife's website, www.cryolife.com, on the Investor Relations page. About CryoLife, Inc.Headquartered in suburban Atlanta, Georgia,

    11/9/21 4:05:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife Reports Third Quarter 2021 Financial Results

    ATLANTA, Nov. 4, 2021 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Achieved total revenues of $72.2 million in the third quarter 2021 versus $65.1 million in the third quarter of 2020, an increase of 11% on a GAAP basis and 9% on a non-GAAP proforma constant currency basis Net income was $10.6 million, or $0.26 per share, in the third quarter of 2021 Non-GAAP net loss was ($1.2) million, or ($0.03) per share, in the third quarter of 2021CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its fina

    11/4/21 4:05:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Horton Amy sold $46,422 worth of shares (2,500 units at $18.57) and gifted 1,500 shares, decreasing direct ownership by 4% to 85,282 units

    4 - CRYOLIFE INC (0000784199) (Issuer)

    12/10/21 4:13:01 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Davis John E bought $10,398 worth of shares (600 units at $17.33), increasing direct ownership by 0.83% to 72,499 units

    4 - CRYOLIFE INC (0000784199) (Issuer)

    12/1/21 4:14:23 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Semedo Anthony B. was granted 4,992 shares and bought $260,400 worth of shares (15,000 units at $17.36)

    4 - CRYOLIFE INC (0000784199) (Issuer)

    11/30/21 4:40:44 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley reiterated coverage on Cryolife with a new price target

    Morgan Stanley reiterated coverage of Cryolife with a rating of Equal-Weight and set a new price target of $25.00 from $29.00 previously

    1/7/22 8:57:55 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    Morgan Stanley reiterated coverage on Cryolife with a new price target

    Morgan Stanley reiterated coverage of Cryolife with a rating of Equal-Weight and set a new price target of $32.00 from $31.00 previously

    7/30/21 11:55:50 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    Needham reiterated coverage on Cryolife with a new price target

    Needham reiterated coverage of Cryolife with a rating of Buy and set a new price target of $39.00 from $38.00 previously

    7/30/21 6:09:23 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    SEC Filings

    View All

    CryoLife Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - ARTIVION, INC. (0000784199) (Filer)

    1/20/22 4:36:16 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form 8-A12B/A filed by CryoLife, Inc. (Amendment)

    8-A12B/A - CRYOLIFE INC (0000784199) (Filer)

    1/6/22 11:45:40 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - CRYOLIFE INC (0000784199) (Filer)

    1/4/22 3:58:05 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Financials

    Live finance-specific insights

    View All

    CryoLife Reports Third Quarter 2021 Financial Results

    ATLANTA, Nov. 4, 2021 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Achieved total revenues of $72.2 million in the third quarter 2021 versus $65.1 million in the third quarter of 2020, an increase of 11% on a GAAP basis and 9% on a non-GAAP proforma constant currency basis Net income was $10.6 million, or $0.26 per share, in the third quarter of 2021 Non-GAAP net loss was ($1.2) million, or ($0.03) per share, in the third quarter of 2021CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its fina

    11/4/21 4:05:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2021 Financial Results

    ATLANTA, Oct. 20, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2021 financial results will be released on Thursday, November 4, 2021 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc. To participate in the conference call dial 862-298-0702 a few minutes

    10/20/21 4:10:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife Reports Second Quarter 2021 Financial Results

    ATLANTA, July 29, 2021 /PRNewswire/ -- Second Quarter and Recent Business Highlights: Achieved total revenues of $76.1 million in the second quarter 2021 versus $53.8 million in the second quarter of 2020, an increase of 42% on a GAAP basis and 35% on a non-GAAP proforma constant currency basis Net loss was ($2.2) million, or ($0.06) per share, in the second quarter of 2021 Non-GAAP net income was $4.8 million, or $0.12 per share, in the second quarter of 2021 CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today i

    7/29/21 4:05:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Leadership Updates

    Live Leadership Updates

    View All

    Anthony Semedo Joins CryoLife Board of Directors

    ATLANTA, Sept. 22, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today the appointment of Anthony "Tony" Semedo to its Board of Directors effective October 1, 2021. "We are thrilled to welcome Tony, a leader in the aortic space, to our board of directors," commented Pat Mackin, Chairman, President, and Chief Executive Officer. "Tony's demonstrated ability to lead, grow, and integrate diversified global divisions in the medical device space as well as his experience managing robust R&D, quali

    9/22/21 4:25:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - CRYOLIFE INC (0000784199) (Subject)

    2/12/21 8:48:51 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed

    SC 13G - CRYOLIFE INC (0000784199) (Subject)

    2/11/21 2:02:44 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - CRYOLIFE INC (0000784199) (Subject)

    2/10/21 10:46:47 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care